online education
Stroke Detection Innovator Wellumio Enrolls First Patient in Australian Clinical Trial for 'Axana' 0.1T portable magnetic resonance imaging device (Portable MRI study)
"Revolutionary portable device leverages advanced magnetic resonancetechnology to rapidly detect acute stroke biomarkers,enabling frontline care teams to make faster,life-saving decisions within
TCL CSOT Showcases Advanced Commercial Display Solutions at ISE 2025
BARCELONA,Spain,Feb. 6,2025-- TCL CSOT,a leading innovator in display technology,is set to present its comprehensive commercial display portfolio at Integrated Systems Europe (ISE) 2025,taking place f
NetEase Cloud Music Inc. to Report Fiscal Year 2024 Financial Results on February 20, 2025
HANGZHOU,China,Feb. 6,2025-- NetEase Cloud Music Inc. (HKEX: 9899 or the "Company"),a leading interactive music streaming service provider in China,today announced that it will report its fi
Silicon Motion First to Achieve ASPICE CL3 for Automotive SSD Controllers
TAIPEI and MILPITAS,Calif.,Feb. 6,2025--Silicon Motion Technology Corporation (NasdaqGS: SIMO) ("Silicon Motion"),a global leader in designing and marketing NAND flash controllers for solid
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG,Jan. 27,2025-- Akeso,Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting mono
Hisense TV Shipment Share at 14.06% in 2024, Maintains Top Two Global Position for Three Consecutive Years
QINGDAO,China,Jan. 26,2025-- Hisense,a leading brand in global consumer electronics and home appliances,has reinforced its dominance in the global TV market achieving an unprecedented three consecutiv
Seeking Investors: First-in-Class Immunotherapeutics for Cancer
ATLANTA,Jan. 27,2025-- Cambium Oncology is pleased to share that their lead drug candidate,ANT308,recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug i
ThinkCyte expands product portfolio to drive innovation in drug discovery and disease research.
TOKYO,Jan. 28,2025-- ThinkCyte,a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis and sorting instruments,announced today that it will begin the pre-commercial
cidaas Applauded by Frost & Sullivan for Its Scalable, Secure, and Comprehensive CIAM Solution
cidaas consistently introduces cutting-edge features to enhance its platform,ensuring alignment with its long-term strategy while addressing evolving industry needs.
IBM and Palo Alto Networks Find Platformization is Key to Reduce Cybersecurity Complexity
Global survey reveals 75% of surveyed organizations pursuing a consolidated approach to security agree better integration across security,hybrid cloud,AI and other technology platforms is crucial